Delivery Order SPE2DB22D2206-SPE2DB25FJV97
- Not listed
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for VIMPAT 10 mg/ml solution in 200 ml quantities, with a ceiling value of $1,048.32. This is a firm fixed-price delivery order with an ultimate completion date of September 4, 2025, awarded on September 3, 2025. The award carries no set-aside designation and was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a $1,455.99 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for VIMPAT 10 mg/mL Solution in 200 mL quantities. This firm fixed price order, with an ultimate completion date of August 4, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was awarded without a set-aside designation through competitive procurement, and performance will occur at the...
- The Defense Logistics Agency awarded a delivery order valued at $1,223.04 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of VIMPAT 10 mg/ml Solution in 200ml quantities. This firm fixed-price delivery order, which is non-set-aside and competitively awarded, will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. VIMPAT (lacosamide) is a prescription anticonvulsant medication used in the treatment of...
- The Defense Logistics Agency awarded a delivery order valued at $1,256.32 to AmerisourceBergen Drug Corp for VIMPAT 10 mg/ml solution in 200ml quantities. This non-competitive delivery order, issued on August 14, 2025, represents a firm fixed-price procurement executed under a child contract arrangement with an ultimate completion date of August 15, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of VIMPAT 10 mg/mL solution in 200 mL quantities, valued at $1,844.01. This is a firm fixed-price delivery order with an ultimate completion date of September 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competitively awarded. VIMPAT (lacosamide) is an antiepileptic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of VIMPAT 100 mg tablets (60-count units) valued at $2,048.51. This firm fixed-price delivery order, which is expected to be completed by August 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was made...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,670.96 to AmerisourceBergen Drug Corp for VIMPAT 10 mg/mL solution (200 mL), a pharmaceutical product used in neurological treatment. This competitively awarded, firm fixed-price delivery order was issued on August 15, 2025, with an ultimate completion date of August 18, 2025. The award carries no set-aside designation and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for VIMPAT 10 mg/ml Solution 200ml, with a ceiling value of $1,136.96 under a firm fixed price contract type. The award was executed on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-set-aside competitive award is being performed at the contractor's facility in Conshohocken, Pennsylvania. VIMPAT (lacosamide) is an anticonvulsant medication used in the treatment of neurological...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of VIMPAT 200 MG tablets in a quantity of 60 units, with a contract ceiling value of $1,089.82. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award through open competition. The contract has an ultimate completion date of July 28, 2025, and AmerisourceBergen will perform this work from its corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of VIMPAT 100 mg at a ceiling value of $1,089.84 under a firm fixed price contract type. This award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the company's larger...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJV97Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,409.40 to AmerisourceBergen Drug Corp for VIMPAT 10 mg/ml solution in a 200 ml volume. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, completed on September 10, 2025, with an ultimate completion date of September 11, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. VIMPAT (lacosamide) is a neurological medication used for seizure management, consistent with the company's extensive portfolio of specialty medications, brand-name and generic drugs, and vaccines delivered across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 9/10/25 |